104 related articles for article (PubMed ID: 3933824)
1. Multiple forms of plasminogen activator in human breast tumors.
O'Grady P; Lijnen HR; Duffy MJ
Cancer Res; 1985 Dec; 45(12 Pt 1):6216-8. PubMed ID: 3933824
[TBL] [Abstract][Full Text] [Related]
2. Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Needham GK; Nicholson S; Angus B; Farndon JR; Harris AL
Cancer Res; 1988 Nov; 48(22):6603-7. PubMed ID: 3141047
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
[TBL] [Abstract][Full Text] [Related]
4. Factors involved in the plasminogen activation system in human breast tumours.
Damjanovich L; Turzó C; Adány R
Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332
[TBL] [Abstract][Full Text] [Related]
5. Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and the presence of metastases in lymph nodes.
Colombi M; Barlati S; Magdelenat H; Fiszer-Szafarz B
Cancer Res; 1984 Jul; 44(7):2971-5. PubMed ID: 6539166
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Kirchheimer JC; Pflüger H; Ritschl P; Hienert G; Binder BR
Invasion Metastasis; 1985; 5(6):344-55. PubMed ID: 4066206
[TBL] [Abstract][Full Text] [Related]
7. [The concentration of tissue--type plasminogen activator (t-PA) in extracts of breast cancer tissue].
Ziółkowska E; Pietrusińska E; Łozyńska-Podhrebelna D
Pol Merkur Lekarski; 2008 Dec; 25(150):489-94. PubMed ID: 19205379
[TBL] [Abstract][Full Text] [Related]
8. Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas.
Sappino AP; Busso N; Belin D; Vassalli JD
Cancer Res; 1987 Aug; 47(15):4043-6. PubMed ID: 2440556
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activators in human nasal polyps and mucosa.
Larsen K; de Maat MP; Jespersen J
Rhinology; 1997 Dec; 35(4):175-7. PubMed ID: 9532638
[TBL] [Abstract][Full Text] [Related]
10. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator system in human breast cancer.
Sumiyoshi K; Serizawa K; Urano T; Takada Y; Takada A; Baba S
Int J Cancer; 1992 Feb; 50(3):345-8. PubMed ID: 1735602
[TBL] [Abstract][Full Text] [Related]
12. Increased plasminogen activator inhibition levels in malignancy.
de Jong E; Knot EA; Piket D; Iburg AH; Rijken DC; Veenhof KH; Dooijewaard G; ten Cate JW
Thromb Haemost; 1987 Apr; 57(2):140-3. PubMed ID: 3110994
[TBL] [Abstract][Full Text] [Related]
13. Human primary colon carcinomas xenografted into nude mice. II. Modulation of tumor plasminogen activator activity by the host tissue environment.
Cajot JF; Sordat B; Bachmann F
J Natl Cancer Inst; 1986 Nov; 77(5):1099-107. PubMed ID: 3095580
[TBL] [Abstract][Full Text] [Related]
14. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
de Vries TJ; Kitson JL; Silvers WK; Mintz B
Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract][Full Text] [Related]
16. Hormonal modulation of plasminogen activator: an approach to prediction of human breast tumor responsiveness.
Mira-y-Lopez R; Ossowski L
Cancer Res; 1987 Jul; 47(13):3558-64. PubMed ID: 3107811
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.
Ganesh S; Sier CF; Griffioen G; Vloedgraven HJ; de Boer A; Welvaart K; van de Velde CJ; van Krieken JH; Verheijen JH; Lamers CB
Cancer Res; 1994 Aug; 54(15):4065-71. PubMed ID: 8033138
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activators and steroid receptor concentrations in normal, benign, and malignant breast and ovarian tissues.
Isotalo H; Tryggvason K; Vierikko P; Kauppila A; Vihko R
Anticancer Res; 1983; 3(5):331-5. PubMed ID: 6685990
[TBL] [Abstract][Full Text] [Related]
19. [Study on the plasma plasminogen activators in patients with malignant gynecologic tumors].
Shimada H; Ikeuchi M; Suwa M; Michimoto T; Ono Y; Tanada S; Himeno K; Hoshino T; Takashima E
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1353-9. PubMed ID: 2511260
[TBL] [Abstract][Full Text] [Related]
20. Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis.
Sumiyoshi K; Baba S; Sakaguchi S; Urano T; Takada Y; Takada A
Thromb Res; 1991 Jul; 63(1):59-71. PubMed ID: 1948823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
